213 related articles for article (PubMed ID: 11872234)
1. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms.
Gansuvd B; Hagihara M; Yu Y; Inoue H; Ueda Y; Tsuchiya T; Masui A; Ando K; Nakamura Y; Munkhtuvshin N; Kato S; Thomas JM; Hotta T
Hum Immunol; 2002 Mar; 63(3):164-75. PubMed ID: 11872234
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells.
Yu Y; Hagihara M; Ando K; Gansuvd B; Matsuzawa H; Tsuchiya T; Ueda Y; Inoue H; Hotta T; Kato S
J Immunol; 2001 Feb; 166(3):1590-600. PubMed ID: 11160200
[TBL] [Abstract][Full Text] [Related]
3. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
4. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L
Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939
[TBL] [Abstract][Full Text] [Related]
5. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
[TBL] [Abstract][Full Text] [Related]
6. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent.
Mori S; Jewett A; Murakami-Mori K; Cavalcanti M; Bonavida B
Cancer Immunol Immunother; 1997 Jul; 44(5):282-90. PubMed ID: 9247563
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway.
Kaser A; Enrich B; Ludwiczek O; Vogel W; Tilg H
Clin Exp Immunol; 1999 Oct; 118(1):71-7. PubMed ID: 10540162
[TBL] [Abstract][Full Text] [Related]
8. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
[TBL] [Abstract][Full Text] [Related]
10. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms.
Kafrouni MI; Brown GR; Thiele DL
J Immunol; 2001 Aug; 167(3):1566-74. PubMed ID: 11466378
[TBL] [Abstract][Full Text] [Related]
11. Localization of Fas ligand in cytoplasmic granules of CD8+ cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity.
Kojima Y; Kawasaki-Koyanagi A; Sueyoshi N; Kanai A; Yagita H; Okumura K
Biochem Biophys Res Commun; 2002 Aug; 296(2):328-36. PubMed ID: 12163021
[TBL] [Abstract][Full Text] [Related]
12. Nasal T/NK cell lymphomas commonly express perforin and Fas ligand: important mediators of tissue damage.
Ohshima K; Suzumiya J; Shimazaki K; Kato A; Tanaka T; Kanda M; Kikuchi M
Histopathology; 1997 Nov; 31(5):444-50. PubMed ID: 9416485
[TBL] [Abstract][Full Text] [Related]
13. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.
Ando K; Hiroishi K; Kaneko T; Moriyama T; Muto Y; Kayagaki N; Yagita H; Okumura K; Imawari M
J Immunol; 1997 Jun; 158(11):5283-91. PubMed ID: 9164947
[TBL] [Abstract][Full Text] [Related]
14. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
Metelitsa LS; Weinberg KI; Emanuel PD; Seeger RC
Leukemia; 2003 Jun; 17(6):1068-77. PubMed ID: 12764370
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
17. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
Aung S; Graham BS
J Immunol; 2000 Apr; 164(7):3487-93. PubMed ID: 10725701
[TBL] [Abstract][Full Text] [Related]
18. IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity.
Bose A; Baral R
Immunol Lett; 2007 Jan; 108(1):68-77. PubMed ID: 17112599
[TBL] [Abstract][Full Text] [Related]
19. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
20. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.
Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC
J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
